OpenEvidence, an AI platform often described as the “ChatGPT for doctors,” is once again making waves in the healthcare technology sector. The startup is set to announce a $200 million funding round at a $6 billion valuation, The New York Times reports. This comes just three months after the company raised $210 million at a $3.5 billion valuation, signaling the growing investor enthusiasm for AI tools tailored to industry-specific needs, particularly in healthcare.
Founded in 2022, OpenEvidence has rapidly emerged as a transformative tool for medical professionals. The platform is trained on peer-reviewed medical literature, including journals such as the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine. Its purpose is to provide verified healthcare professionals with quick, accurate answers to clinical questions, enabling them to make better-informed decisions at the point of care. Notably, the platform is free for verified doctors and nurses, supported through advertising.
The adoption of OpenEvidence has skyrocketed in a short time. According to The New York Times, the number of clinical consultations conducted on the platform has nearly doubled since July, now reaching 15 million per month. This rapid growth reflects the demand for AI tools that help clinicians navigate an overwhelming volume of medical research efficiently, while maintaining the highest standards of accuracy and reliability.
The latest funding round is led by Google Ventures, with participation from top-tier investors such as Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. With this round, OpenEvidence has raised over $500 million in total since its inception, highlighting strong investor confidence in the company’s vision and growth trajectory.
OpenEvidence exemplifies a broader trend of AI solutions focusing on specialized applications rather than generic use cases. Tools like DeepConsult within the platform assist clinicians in analyzing complex medical data, synthesizing research findings, and making timely treatment decisions. By doing so, OpenEvidence not only enhances efficiency but also has the potential to improve patient outcomes, a key metric for healthcare innovation.
The company has also made strategic moves to strengthen its infrastructure and capabilities. Recent acquisitions, including AI startup Amaro, aim to expand its platform’s functionality and ensure sustainable, scalable growth. Industry observers note that the combination of a rapidly expanding user base, strong investor backing, and cutting-edge AI technology positions OpenEvidence as a leader in the next generation of clinical decision support systems.
In just three years, OpenEvidence has transformed from a promising concept into a major player in healthcare AI. With continued investment and adoption, the platform is poised to redefine how medical professionals access, interpret, and apply critical clinical knowledge, ultimately shaping the future of patient care.
